moxifloxacin has been researched along with chlorogenic acid in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (chlorogenic acid) | Trials (chlorogenic acid) | Recent Studies (post-2010) (chlorogenic acid) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 3,276 | 76 | 2,241 |
| Protein | Taxonomy | moxifloxacin (IC50) | chlorogenic acid (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 7.9 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.95 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 1.05 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 0.1 | |
| large T antigen | Betapolyomavirus macacae | 14.67 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for moxifloxacin and chlorogenic acid
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |